查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1801145

2025 年至 2033 年人類生長激素市場規模、佔有率、趨勢及預測（按應用、配銷通路、給藥途徑和地區）

Human Growth Hormone Market Size, Share, Trends and Forecast by Application, Distribution Channel, Route of Administration, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 119 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球人類生長激素市場規模為61.1億美元。展望未來， IMARC Group估計，到2033年，市場規模將達到114.7億美元，2025-2033年期間的複合年成長率為6.88%。目前，北美佔據市場主導地位，2024年將佔據42.8%的顯著市場。由於醫療基礎設施發達，以及生長激素缺乏症、特納氏症和普拉德-威利氏症等HGH相關疾病的高發生率，市場正在強勁成長。政府以優惠報銷政策形式提供的支持、輝瑞和禮來等領先製藥公司的供應以及重組DNA方法的進步，也推動了人類生長激素市場佔有率的成長。

由於生長激素缺乏症（包括生長激素減退症）的發生率不斷上升，人類生長激素 (HGH) 市場正在快速成長。生物技術和重組 DNA 技術的進步使得合成 HGH 成為可能，從而提高了 HGH 的可及性和可負擔性。人口老化以及由此導致的荷爾蒙缺乏也催生了對 HGH 療法的強勁需求。長效產品和易於使用的設備等藥物輸送系統的技術進步，提高了患者的依從性和易用性。此外，患者和醫護人員對 HGH 療法優勢的認知不斷提高，也有助於推動市場成長。發展中經濟體醫療基礎設施的不斷完善為市場滲透提供了尚未開發的潛力。此外，個人化醫療和精準治療的日益流行，使得 HGH 療法能夠實現個人化，從而最大限度地提高療效並減少副作用。

美國憑藉其先進的醫療體系、健全的監管體系和尖端的製藥業格局，成為市場的關鍵顛覆者。美國公司在研發新型人類生長激素（HGH）產品方面處於領先地位，例如長效且患者友善的製劑，這些產品正在徹底改變全球的治療模式。美國積極主動的監管體系支持創新療法的快速核准和商業化，為其他全球市場樹立了榜樣。此外，患者和醫療保健專業人士的高度認知也促進了新療法的早期應用。對研發和生物技術的大量投入進一步加速了產品創新和競爭，迫使全球企業紛紛效仿美國標準。個人化醫療和數位健康解決方案的結合也提高了治療的準確性和患者的依從性。因此，美國在引領產品發展的同時也改變了市場預期，使其成為全球人類生長激素（HGH）市場領域的潮流引領者和顛覆者。

人類生長激素市場趨勢：

越來越重視個人化治療和預防性治療以及其他疾病

改變人類生長激素 (HGH) 行業最顯著的趨勢之一是越來越重視個人化和預防性醫療保健方法。隨著醫學科學的不斷發展，治療方法正從通用方案轉向針對患者基因、習慣和個別荷爾蒙缺乏情況的客製化方案。這一趨勢在 HGH 市場尤其顯著，因為治療持續時間和劑量會根據患者的年齡、病情和代謝反應而有很大差異。醫生擴大使用診斷工具和數位監測技術來改進荷爾蒙療法，從而獲得更好的療效並減少副作用。預防措施也正在取得進展，HGH 正被用於研究如何治療生長激素缺乏症，以及與年齡相關的退化、創傷復原和慢性疲勞。此外，特納氏症和其他生長相關疾病的盛行率不斷上升是推動市場成長的關鍵因素之一。特納氏症是一種主要影響女性的染色體疾病，其特徵是 X 染色體完全或部分缺失，大約每 2,500 名女嬰中就有 1 名患有此病。生長激素通常用於緩解疾病的部分症狀，從而增加了全球對人類生長激素（HGH）藥物的需求。這些用途的拓展不僅拓寬了市場範圍，也滿足了消費者對健康和長壽解決方案日益成長的興趣，進一步推動了人類生長激素市場的成長。

藥物輸送系統的技術進步

藥物輸送系統的多項進步是推動人類生長激素市場成長和創新的另一個主要趨勢。傳統的人類生長激素（HGH）療法歷來採用頻繁甚至每日注射的形式，這給兒科和老年患者帶來了依從性挑戰。解決這個問題的方案是製藥業持續投資開發長效製劑、注射筆，甚至透皮貼片和自動注射器。這些技術顯著提高了患者的便利性，減輕了治療負擔，使人類生長激素（HGH）療法更容易取得，也更輕鬆便捷。更先進的藥物傳遞技術還能提高血液中荷爾蒙水平的穩定性，減少副作用，並提高療效。因此，這一趨勢是生物製藥市場普遍轉向以患者為中心的產品設計趨勢的延伸。此外，隨著競爭的加劇，製藥公司將易用性和患者滿意度作為差異化因素。最終，這些技術進步不僅提升了治療效果，也改變了使用者體驗，並增強了市場對廣泛患者群體的吸引力。

擴展到非傳統和健康應用

根據人類生長激素市場預測，市場正在從傳統的醫療應用擴展到更廣泛的健康、運動和美容領域。儘管人類生長激素 (HGH) 仍然是治療生長激素缺乏症和特納氏症的重要療法，但其在抗衰老、增肌和代謝健康方面的公認優勢正在生活方式和選擇性醫療保健市場掀起波瀾。提供荷爾蒙替代療法的診所越來越受到追求青春活力和健康體魄的老年人群的青睞。儘管此類應用通常存在爭議且需接受監管，但隨著人們對長壽和生活品質的認知和興趣日益成長，需求仍然強勁。這正在創造新的市場動態，因為傳統製藥公司發現自己正在與私人健康診所和整合醫學機構競爭。醫療需求與生活方式改善的融合帶來了許多機會。因此，人類生長激素 (HGH) 產業正在轉型成為一個高度複雜的生態系統，因為它同時受到臨床需求和消費者需求的雙重驅動。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球人類生長激素市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依應用

  • 生長激素（GH）缺乏症
    • 主要類型
      • 成人生長激素缺乏症
      • 兒童生長激素缺乏症
  • 特納氏症
  • 特發性身材矮小（ISS）
  • 普拉德-威利症候群（PWS）
  • 小於胎齡兒
  • 其他

第7章：市場區隔：按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 其他

第8章：市場區隔：依行政途徑

  • 靜脈
  • 肌肉注射
  • 皮下
  • 口服

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章：SWOT分析

第 11 章：價值鏈分析

第 12 章：波特五力分析

第 13 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Eli Lilly and Company
    • EMD Serono Inc.
    • F. Hoffmann-La Roche AG
    • Ferring BV
    • Genentech Inc.
    • Ipsen
    • Merck KGaA
    • Novartis AG
    • Novo Nordisk
    • Pfizer Inc.
    • Sandoz
Product Code: SR112025A2052

The global human growth hormone market size was valued at USD 6.11 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 11.47 Billion by 2033, exhibiting a CAGR of 6.88% during 2025-2033. North America currently dominates the market, holding a significant market share of 42.8% in 2024. The market is growing robustly due to the developed healthcare infrastructure and high incidence of HGH-related disorders like growth hormone deficiencies, Turner syndrome, and Prader-Willi syndrome. Government support in the form of favorable reimbursement policies, availability of leading pharmaceutical firms, including Pfizer and Eli Lilly, and advancements in recombinant DNA methods have also fueled the human growth hormone market share.

The market for human growth hormone (HGH) is witnessing rapid growth due to rising incidences of deficiencies of the growth hormone, including hyposomatotropism. Improvements in biotechnology and recombinant DNA technology have made it possible to produce synthetic HGH, and hence there is improvement in accessibility and affordability. The aging population and the resultant hormone deficiencies due to old age also create a strong demand for HGH therapies. Technological advancements in drug delivery systems, such as long-acting products and easy-to-use devices, improve patient compliance and ease of use. Moreover, increasing awareness among patients and medical practitioners regarding the advantages of HGH therapy helps support market growth. Growing healthcare infrastructure in developing economies provides untapped potential for market penetration. In addition, the growing trend of personalized medication and precision therapeutics enables specialized HGH therapies, maximizing yields and reducing adverse effects.

The United States stands out as a key market disruptor, driven by its advanced health system, robust regulatory system, and cutting-edge pharma landscape. American companies are at the forefront in creating new HGH products, such as long-acting and patient-friendly formulations, that are revolutionizing treatment patterns throughout the world. The proactive regulatory system of the country supports quick approval and commercialization of innovative therapies, leading the way for other global markets. Moreover, high awareness among patients and healthcare professionals also fuels early adoption of new treatments. Heavy investment in research and biotechnology further accelerates product innovation and competition, forcing global players to catch up with US standards. The incorporation of personalized medicine and digital health solutions also improves treatment accuracy and patient compliance. Consequently, the US shapes product development while also altering market expectations, positioning it as a trendsetter and a disruptor in the global HGH market space.

Human Growth Hormone Market Trends:

Growing Emphasis on Personalized and Preventive Therapies and Other Disorders

One of the most prominent trends transforming the human growth hormone (HGH) industry is growing emphasis on personalized and preventive healthcare methods. As medical science continues to evolve, treatments are departing from generic protocols to customized regimens specific to a patient's genetics, habits, and individual hormonal deficiencies. This trend is especially significant in the HGH market, where treatment duration and dosages can dramatically differ based on the patient's age, condition, and metabolic response. Doctors are increasingly using diagnostic tools and digital monitoring technologies to refine hormone therapies, producing improved results with fewer side effects. Preventive measures are also making inroads, with HGH being investigated for deficiency disorders, and also for age-related degeneration, trauma recovery, and chronic fatigue. Moreover, the increasing prevalence of Turner syndrome and other growth-related disorders is one of the key factors driving the growth of the market. Turner syndrome is a chromosomal disorder that primarily affects females and is characterized by complete or partial loss of X chromosomes, occurring in approximately one in 2,500 female babies. Growth hormones are often administered to reverse some of the symptoms of this disease, thereby increasing the demand for HGH drugs across the globe. These expanded uses are broadening the market scope while responding to increasing consumer interest in wellness and longevity solutions, further fueling the human growth hormone market growth.

Technological Advances in Drug Delivery Systems

Several advancements in drug delivery systems are another principal trend propelling growth and innovation in the market for human growth hormone. Conventional HGH therapy was historically in the form of frequent, even daily injections, which imposed compliance challenges among pediatric and aged patients. The solution to this is the ongoing investment by the pharmaceutical industry to develop long-duration formulations, pen devices, and even transdermal patches and auto-injectors. These technologies are considerably improving patient convenience and treatment burden reduction, making HGH therapy more available and less daunting. Better drug delivery technology also improves stability in terms of hormone levels in the blood, reducing side effects and improving therapeutic efficacy. The trend is therefore an extension of a general shift toward patient-centered product design in the biopharmaceutical market. Moreover, with the rise in competition, pharmaceutical companies are focusing on ease of use and patient satisfaction as differentiators. Ultimately, these advances in technology are enhancing treatment outcomes, while also transforming user experience and broadening the market's appeal across a wide range of patient segments.

Expansion into Non-Traditional and Wellness Applications

The market is expanding beyond conventional medical applications into wider wellness, sports, and aesthetic uses, as per the human growth hormone market forecast. Although HGH is still an important therapy for growth hormone deficiency and Turner syndrome, its perceived virtues in anti-aging, muscle building, and metabolic well-being are creating waves in lifestyle and elective healthcare markets. Clinics that provide hormone replacement therapy are becoming increasingly popular among older age groups that aim to stay youthful and physically fit. While such applications are usually contentious and subject to regulatory oversight, demand remains strong, driven by increasing awareness and interest in longevity and quality of life. This is creating new market dynamics, as conventional pharmaceutical companies find themselves competing with private wellness clinics and integrative medicine practices. The convergence of medical necessity and lifestyle enhancement is hence giving rise to several opportunities. Consequently, the HGH industry is transforming itself into a highly sophisticated ecosystem as it is governed by both clinical necessities and consumer desires.

Human Growth Hormone Industry Segmentation:

Analysis by Application:

  • Growth Hormone (GH) Deficiency
    • Adult GH Deficiency
    • Pediatric GH Deficiency
  • Turner Syndrome
  • Idiopathic Short Stature (ISS)
  • Prader-Willi Syndrome (PWS)
  • Small for Gestational Age
  • Others

Growth hormone (GH) deficiency stands as the largest component in 2024. Growth hormone deficiency continues to dominate the human growth hormone (HGH) industry's leading applications segment, spearheaded by the proven clinical application and steady demand for both pediatrics and adult patient populations. GH deficiency among children can cause dwarfism, delayed puberty, and other aspects of developmental shortcomings, thus prompt diagnosis and management are imperative. Among adults, GH deficiency primarily manifests as lost muscle mass, lethargy, and declining metabolic function. The obvious therapeutic advantage of HGH in treating these symptoms guarantees long-term market demand. Physicians prescribe HGH therapy as routine treatment, underpinned by robust clinical guidelines and long-term outcome evidence. This segment also enjoys the advantage of ongoing research, which continues to optimize treatment protocols and enhance patient monitoring. The diagnosability of GH deficiency, along with improvements in diagnostic equipment and greater recognition by healthcare practitioners, reinforces its position as the cornerstone application supporting steady growth as observed throughout the human growth hormone market report.

Analysis by Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Hospital pharmacy leads the market with around 47.9% of market share in 2024. Hospital pharmacies are the primary channel of distribution in the human growth hormone (HGH) market because they can provide safe, regulated, and consistent access to hormone therapy. These pharmacies are usually the first point of dispensing for patients with complicated or chronic endocrine disorders, such as growth hormone deficiency. Hospitals provide an ordered setting for prescribing, administration, and patient supervision, a situation necessary for drugs requiring stringent dosing and monitoring. They are also generally centers for consolidated master plans involving treatment under specialists that endocrinologists and pediatricians coordinate, another guaranteeing element for them as a supplier of HGH. Moreover, hospitals are patient education centers and programs assuring maximization in therapeutic intervention. With stricter regulation and the necessity for high-standard storage and handling of biologics such as HGH, hospital pharmacies are adequately positioned to achieve compliance levels. Their place within larger healthcare delivery systems ensures that they are a reliable and trusted channel, playing an important role in ensuring the stability and growth of the HGH market.

Analysis by Route of Administration:

  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Oral

Subcutaneous leads the market with around 33.7% of market share in 2024. Subcutaneous administration is the most predominant mode of administration in the human growth hormone (HGH) industry because it is effective, convenient, and patient-compliant. Subcutaneous injections are unlike intravenous (IV) injections, which must be administered under clinical observation, as they can be self-administered by patients in their own homes, thus the best for maintenance hormone therapy. This technique consists of injecting HGH into the fat tissue directly under the skin, so it can be slowly and steadily absorbed into the body. It is also less intrusive than other techniques, with lower risks of complications like infection or damage to the blood vessels. With time, improvements in the injection equipment, including pre-filled syringes, auto-injectors, and pen devices, have further simplified subcutaneous administration. These innovations increase patient comfort, simplify the treatment process, and enhance compliance. Considering these factors, subcutaneous injections are the favored and most adopted mode of administration for HGH treatments, fueling growth within the HGH market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest market share of over 42.8%. North America is the leading regional segment in the worldwide human growth hormone (HGH) market, fueled by a mix of sophisticated healthcare infrastructure, strong research and development activities, and a high incidence of growth hormone deficiencies. The United States, especially, is instrumental, with a major market share due to its well-established healthcare systems and pervasive availability of HGH therapies. This dominance is complemented by supportive reimbursement policies and government actions that enable patient access to treatments that are essential. Major pharmaceutical corporations headquartered in North America, including Pfizer and Eli Lilly, drives the market growth by ensuring ongoing innovation and the establishment of new HGH products. While, these innovations enhance the effectiveness of treatments, they also optimize patient compliance and quality of life. The region's dedication to healthcare excellence guarantees a consistent demand for HGH treatments, cementing its status as the top market segment. In the future, North America's market share is likely to continue its upward growth, driven by continued investment in healthcare infrastructure and growing public awareness about growth hormone deficiency. With the region continuing to dominate both in terms of market size and innovation, it also sets the standard for HGH therapy practice globally.

Key Regional Takeaways:

United States Human Growth Hormone Market Analysis

In 2024, the United States accounted for over 91.80% of the human growth hormone market in North America. The United States human growth hormone (HGH) market is witnessing sustained growth, driven by increasing awareness about hormone-related disorders and a growing emphasis on physical health and wellness. An increase in the elderly population, with the count of Americans aged 65 and above expected to reach 82 million by 2050, is fueling the rising demand for hormone replacement therapies (PRB). Additionally, the expanding use of HGH in managing conditions associated with growth hormone deficiency and improved diagnostic capabilities is fueling market demand. Supportive healthcare infrastructure, along with a rise in specialized treatment centers, further boosts market growth. Technological advancements in drug delivery methods and increasing healthcare expenditure are enhancing accessibility and treatment adherence. The expanding scope of therapeutic applications beyond traditional uses is also stimulating market interest. Investment in medical research, regulatory support, personalized medicine, preventive healthcare, fitness consciousness, hormone therapy uses, digital health integration, and early diagnosis awareness are driving market growth.

Europe Human Growth Hormone Market Analysis

The human growth hormone market in Europe is expanding steadily due to increased recognition of endocrine disorders and broader acceptance of hormonal therapies. An aging demographic and the growing focus on improving quality of life are fueling the demand for growth hormone treatment options. The European Pharmaceutical Review states that biosimilar competition in Europe has significantly increased patient access to key biological medicines, with healthcare budget reductions amounting to €56 billion across Europe and approx. €6 billion in 2024 alone. This trend supports the wider adoption of growth hormone therapies by making them more affordable and accessible. The market for hormone therapies is thriving due to advancements in healthcare systems, advanced diagnostic tools, research and development efforts, public health initiatives, digital technology integration, continuous medical education programs, and the growing perception of hormone therapies as part of overall wellness strategies. With rising healthcare investments and a focus on preventive care, the market is poised for continued expansion.

Asia Pacific Human Growth Hormone Market Analysis

The Asia Pacific human growth hormone market outlook is experiencing robust growth, fueled by increasing healthcare awareness and rising demand for hormone-based therapies. Improved healthcare access and infrastructure across developing regions are enhancing diagnosis and treatment rates. A growing population and a heightened focus on child development are also contributing to market expansion. According to the India Brand Equity Foundation, the Indian healthcare market, valued at USD 110 Billion in FY16, is now projected to reach USD 638 Billion by FY25, further indicating the growing healthcare needs in the region. The adoption of advanced medical technologies and an escalating interest in personalized treatment are strengthening therapeutic approaches. Enhanced government health initiatives and greater public awareness about hormone-related disorders are accelerating market activity. Furthermore, the demand for better quality of life and rising investment in medical innovation are supporting long-term growth. The market outlook remains positive, driven by changing lifestyle patterns and increased health consciousness across urban populations.

Latin America Human Growth Hormone Market Analysis

The Latin American human growth hormone market is expanding due to increased public awareness, healthcare coverage, and improved medical infrastructure. The market is driven by a rising focus on growth and developmental health, hormone therapy adoption, and general wellness promotion. Additionally, the region is benefitting from continuous initiatives aimed at improving healthcare service delivery, as Brazil's local manufacturing of medical supplies satisfies 42% of the population's requirements. With the New Industry Brazil (NIB) initiative, the government seeks to elevate this percentage to 50% by 2026 and to 70% by 2033, which will enhance market potential by facilitating access to therapeutic solutions. These combined initiatives are setting the area up for ongoing expansion in the HGH market.

Middle East and Africa Human Growth Hormone Market Analysis

The Middle East and Africa human growth hormone market is expanding due to increased awareness about endocrine health, improved healthcare access, investments in medical facilities, health education, demand for advanced therapies, and long-term wellness focus. This growth is fueled by increased support for health infrastructure. Additionally, the growing medical tourism sector in the region plays a significant role in market expansion. With ongoing developments in healthcare provision and a shift toward preventive care practices, the market is poised for further advancement. These factors collectively contribute to the promising outlook of the region's HGH market.

Competitive Landscape:

Major companies in the human growth hormone market are developing growth through different strategic initiatives, such as product development innovation, strategic alliances, and increased patient accessibility programs. Major pharmaceuticals like Novo Nordisk, Pfizer, Eli Lilly, and Merck are investing in developing future-generation HGH products, including long-acting or sustained-release products, that decrease the number of injections and increase patient compliance. These innovations are intended to make treatment more convenient for pediatric as well as adult patients, resulting in better therapeutic results. These firms also invest heavily on research and development to identify new uses for HGH, such as in anti-aging and metabolic health, broadening the scope of the market beyond conventional deficiency treatments. Additionally, key players are establishing strategic alliances and partnerships with healthcare professionals, academic centers, and research centers to increase market presence and widen clinical evidence backing HGH treatments. These partnerships facilitate quicker product development and lead to bringing new solutions to the market more efficiently. In order to enhance patient accessibility, firms are collaborating with payers and regulatory agencies to rationalize approval processes and make HGH therapies widely available and affordable. Consequently, these initiatives are driving market growth, improving the overall efficacy of HGH treatment, and responding to the heterogeneous needs of the patient base.

The report provides a comprehensive analysis of the competitive landscape in the human growth hormone market with detailed profiles of all major companies, including:

  • Eli Lilly and Company
  • EMD Serono Inc.
  • F. Hoffmann-La Roche AG
  • Ferring B.V.
  • Genentech Inc.
  • Ipsen
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk
  • Pfizer Inc.
  • Sandoz

Key Questions Answered in This Report

  • 1.How big is the human growth hormone market?
  • 2.What is the future outlook of human growth hormone market?
  • 3.What are the key factors driving the human growth hormone market?
  • 4.Which region accounts for the largest human growth hormone market share?
  • 5.Which are the leading companies in the global human growth hormone market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Human Growth Hormone Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Application

  • 6.1 Growth Hormone (GH) Deficiency
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Adult GH Deficiency
      • 6.1.2.2 Pediatric GH Deficiency
    • 6.1.3 Market Forecast
  • 6.2 Turner Syndrome
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Idiopathic Short Stature (ISS)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Prader-Willi Syndrome (PWS)
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Small for Gestational Age
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Distribution Channel

  • 7.1 Hospital Pharmacy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Retail Pharmacy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Online Pharmacy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Intravenous
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Intramuscular
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Subcutaneous
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Oral
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Eli Lilly and Company
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 EMD Serono Inc.
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 F. Hoffmann-La Roche AG
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 SWOT Analysis
    • 13.3.4 Ferring B.V.
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
    • 13.3.5 Genentech Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 SWOT Analysis
    • 13.3.6 Ipsen
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
    • 13.3.7 Merck KGaA
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
    • 13.3.8 Novartis AG
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
    • 13.3.9 Novo Nordisk
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
    • 13.3.10 Pfizer Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Sandoz
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio

List of Figures

  • Figure 1: Global: Human Growth Hormone Market: Major Drivers and Challenges
  • Figure 2: Global: Human Growth Hormone Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Human Growth Hormone Market: Breakup by Application (in %), 2024
  • Figure 4: Global: Human Growth Hormone Market: Breakup by Distribution Channel (in %), 2024
  • Figure 5: Global: Human Growth Hormone Market: Breakup by Route of Administration (in %), 2024
  • Figure 6: Global: Human Growth Hormone Market: Breakup by Region (in %), 2024
  • Figure 7: Global: Human Growth Hormone Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 8: Global: Human Growth Hormone (Growth Hormone Deficiency) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Human Growth Hormone (Growth Hormone Deficiency) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Human Growth Hormone (Turner Syndrome) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Human Growth Hormone (Turner Syndrome) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Human Growth Hormone (Idiopathic Short Stature- ISS) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Human Growth Hormone (Idiopathic Short Stature- ISS) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Human Growth Hormone (Prader-Willi Syndrome- PWS) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Human Growth Hormone (Prader-Willi Syndrome- PWS) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Human Growth Hormone (Small for Gestational Age) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Human Growth Hormone (Small for Gestational Age) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Human Growth Hormone (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Human Growth Hormone (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Human Growth Hormone (Hospital Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Human Growth Hormone (Hospital Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Human Growth Hormone (Retail Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Human Growth Hormone (Retail Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Human Growth Hormone (Online Pharmacy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Human Growth Hormone (Online Pharmacy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Human Growth Hormone (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Human Growth Hormone (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Human Growth Hormone (Intravenous) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Human Growth Hormone (Intravenous) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Human Growth Hormone (Intramuscular) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Human Growth Hormone (Intramuscular) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Human Growth Hormone (Subcutaneous) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Human Growth Hormone (Subcutaneous) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Human Growth Hormone (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Human Growth Hormone (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: North America: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: North America: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: United States: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: United States: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Canada: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Canada: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Asia Pacific: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Asia Pacific: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: China: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: China: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Japan: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Japan: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: India: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: India: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: South Korea: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: South Korea: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Australia: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Australia: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Indonesia: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Indonesia: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Others: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Others: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Europe: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Europe: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Germany: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Germany: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: France: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: France: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: United Kingdom: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: United Kingdom: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Italy: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Italy: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Spain: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Spain: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Russia: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Russia: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Latin America: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Latin America: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Brazil: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Brazil: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Mexico: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Mexico: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Others: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Others: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Middle East and Africa: Human Growth Hormone Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Middle East and Africa: Human Growth Hormone Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Global: Human Growth Hormone Industry: SWOT Analysis
  • Figure 85: Global: Human Growth Hormone Industry: Value Chain Analysis
  • Figure 86: Global: Human Growth Hormone Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Human Growth Hormone Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Human Growth Hormone Market Forecast: Breakup by Application (in Million USD), 2025-2033
  • Table 3: Global: Human Growth Hormone Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 4: Global: Human Growth Hormone Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 5: Global: Human Growth Hormone Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Human Growth Hormone Market: Competitive Structure
  • Table 7: Global: Human Growth Hormone Market: Key Players